Vertex Pharmaceuticals is a large-cap biotechnology company best known for its cystic fibrosis (CF) franchise, with expanding franchises in pain, gene editing, and kidney disease. The $575 central target used here is not a headline consensus figure copied from a single site; it is the arithmetic mean of roughly 22 individual, attributable analyst targets reviewed across sources, spanning roughly $350 to $667.
That wide range reflects genuine disagreement. At the bullish end, BofA Securities holds a $667 target, Morgan Stanley resumed coverage with a $665 target, and Goldman Sachs carries a $654 target after adding the stock to its US Conviction List. UBS raised its target to $615, Jefferies to $640, H.C. Wainwright to $641, and BMO Capital maintained $600. In the middle, Citi sits at $585, RBC Capital at $576, and J.P. Morgan at $560. The cautious end is starkly different: Stifel holds at $445, and Baird carries a $350 target with a Sell rating—the lone outright bearish call among the names reviewed.
Most bullish analysts cite the durability of the CF business, promising Phase 2b data for the kidney drug inaxaplin, and diversification from the completed acquisition of Crinetics Pharmaceuticals (CRNX). The skeptics generally point to valuation and the assumption that pipeline risk is not yet fully reflected in the share price.
VRTX recently traded around $514.65, roughly in the middle of its 52-week range of about $403 to $560. A move to $575 would represent an increase of approximately 12%, which is a modest step for a large-cap biotech name but one that would still require the stock to clear its prior 52-week high and establish new all-time-high territory.
The path toward that level most plausibly runs through continued CF revenue growth, early contributions from newer products such as Alyftrek, Casgevy, and Journavx, and de-risking of the kidney pipeline. The company has raised its 2026 revenue guidance to a range of $13.1 billion to $13.2 billion, and trailing twelve-month revenue of about $12.6 billion was up roughly 10% year over year. If execution continues, the target reflects a valuation argument as much as a fundamental one: analysts are effectively asking the market to keep paying a premium multiple for above-peer growth and pipeline optionality.
Several verifiable factors support the bullish case. The Phase 2b AMPLIFIED study of inaxaplin in APOL1-mediated kidney disease showed a roughly 43% reduction in urine albumin-to-creatinine ratio in patients with moderate proteinuria, which several firms read as a meaningful de-risking event for a large potential market. The Crinetics acquisition broadens the company beyond CF, and new Alyftrek data were expected at the North American Cystic Fibrosis Conference. CF itself remains a highly profitable, durable franchise with strong pricing power and limited near-term competition, supporting the cash flow that funds Vertex's pipeline.
The principal obstacle is valuation. At a market capitalization near $129 billion, the stock embeds meaningful expectations for future pipeline success, leaving limited room for disappointment. Clinical trials and regulatory decisions are inherently uncertain, and the Crinetics deal adds integration and execution risk. Competition in CF and emerging franchises, a slower-than-expected launch of newer products, or a guidance cut could compress the multiple quickly. The presence of a $350 Sell target—well below the current price—is a reminder that not every analyst agrees the growth story justifies today's valuation.
The most relevant technical level is the 52-week high near $560, which sits just below the $575 target and acts as resistance; a decisive move above it would mark a breakout to new highs. On the downside, the $500 round-number level and the $403 area near the 52-week low provide the clearest structural reference points. The stock's recent consolidation below $560 suggests the target would require buyers to absorb supply at that prior peak before extending higher.
Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms apply different assumptions about earnings, valuation, and pipeline probability. The next major catalyst is Vertex's third-quarter 2026 earnings report, scheduled for November 2, 2026, where investors will focus on CF revenue, updated guidance, and commentary on the Crinetics integration. Beyond that, Phase 3 kidney data expected in early 2027, new product launches, analyst revisions, and broader sector rotation into or out of large-cap biopharma will all matter for whether the stock can hold and extend toward the target.
For traders who prefer a systematic, data-driven approach to timing, Tickeron's AI Daily Buy/Sell Signals offer a way to monitor names like VRTX without manually tracking every chart. The tool uses artificial intelligence to continuously scan thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. It is designed to help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening alone. Explore the AI Daily Buy/Sell Signals to see how automated signal monitoring can fit into your research routine.
The $575 central target is the arithmetic mean of roughly 22 verified analyst price targets ranging from $350 to $667, and it implies a modest upside of about 12% from a recent price near $514.65. The case for reaching it rests on a durable CF franchise, encouraging inaxaplin data, the Crinetics acquisition, and broadly positive analyst revisions. The case against rests on a demanding valuation, clinical and regulatory risk, and a wide dispersion of opinion that includes a Sell rating well below the current price. Whether VRTX reaches $575 will depend on continued execution and on whether the market continues to reward the company's pipeline optionality—an outcome that is plausible but by no means guaranteed.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, VRTX has been loosely correlated with RPRX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if VRTX jumps, then RPRX could also see price increases.
| Ticker / NAME | Correlation To VRTX | 1D Price Change % | ||
|---|---|---|---|---|
| VRTX | 100% | +1.95% | ||
| RPRX - VRTX | 45% Loosely correlated | +1.71% | ||
| INCY - VRTX | 45% Loosely correlated | -0.06% | ||
| EDIT - VRTX | 44% Loosely correlated | -0.68% | ||
| BMRN - VRTX | 43% Loosely correlated | +2.66% | ||
| REGN - VRTX | 43% Loosely correlated | +0.68% | ||
More | ||||